Drugs & Targets FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer April 24, 2026Vol.52 No.16
Health EquityRegulatory News Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line April 17, 2026Vol.52 No.15By Claire Marie Porter
Cancer Policy FDA adds stereotactic breast biopsy needles to the shortage list April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy FDA issues reminder to sponsors: Disclose clinical trial results April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Drugs & Targets FDA issues draft guidance on genome editing safety standards April 17, 2026Vol.52 No.15
Drugs & Targets FDA clears first HPV self-collection kit and assay for at-home use, marking a step toward improving screening uptake April 10, 2026Vol.52 No.14
Drugs & Targets Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC April 10, 2026Vol.52 No.14
News Analysis HHS presents new protein-forward dietary guidelines, turning the food pyramid upside downThe Kennedy guidelines are mum on cancer risks associated with red meat and alcohol April 03, 2026Vol.52 No.13By Claire Marie Porter
FreeGuest Editorial FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers April 03, 2026Vol.52 No.13By Nicholas Richardson
